

SciClone Pharmaceuticals to Present at Two Investor Conferences in May

**Rodman & Renshaw Annual London Investment Conference on Monday, May 17 at 4:05 pm GMT;
Oppenheimer Annual China Dragon Call Conference on Tuesday, May 18 at 4:40 pm ET**

FOSTER CITY, CA, May 10, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Rodman & Renshaw Annual London Investment China Conference, and the Oppenheimer Annual China Dragon Call Conference. SciClone's executives will present a corporate overview and business update at each conference.

Rodman & Renshaw Annual London Investment Conference

Monday, May 17; 4:05 pm GMT

London, UK

Presenter: Friedhelm Blobel, Ph.D., President and CEO

Webcast: To access the live audio webcasts of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

Oppenheimer Annual China Dragon Call Conference

Tuesday, May 18; 4:40 pm ET

New York City, NY

Presenter: Gary Titus, Senior Vice President and CFO

Presentations made at this conference are not being webcast.

About SciClone SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-focused, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN(R) (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in clinical studies as an enhancer of vaccines; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead(TM) in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm(TM) in China, including Hong Kong and Macau, and Vietnam, for which it will seek regulatory approval. For additional information, please visit www.sciclone.com.

SOURCE: SciClone Pharmaceuticals, Inc.

Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX